APA, CTIC, TSRX - CRWESelect.com Stock News! Apache Corporation, Cell Therapeutics, Trius Therapeutics (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) January 23, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28287/stock-alerts/apa-ctic-tsrx-crweselectcom-stock-news-apache-corporation-cell-therapeutics-trius-therapeutics-video-included-inside/

Apache Corporation (NYSE: APA)

APA announced today that it has agreed to acquire Cordillera Energy Partners III LLC, a privately held company with substantial operations that include approximately 254,000 net acres in the prolific Granite Wash, Tonkawa, Cleveland and Marmaton plays in western Oklahoma and the Texas Panhandle, for $2.85 billion.

APA is an oil and gas exploration and production company with operations in the United States, Canada, Egypt, the United Kingdom North Sea, Australia and Argentina.

For more information about APA please visit http://www.apachecorp.com

****

Cell Therapeutics, Inc. (NASDAQ: CTIC)

CTIC expects that the European Medicines Agency's Committee for Medicinal Products for Human Use may issue an opinion on the marketing authorization application on Pixuvri in mid-february.

Headquartered in Seattle, CTIC is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

For more information about CTIC please visit http://www.celltherapeutics.com

*****

Trius Therapeutics, Inc. (NASDAQ: TSRX)

TSRX announced today that it has earned a $5 million milestone payment from Bayer Healthcare for the achievement of all efficacy and safety objectives in the TR701-112 Phase 3 pivotal study which tested the oral dosage form of tedizolid phosphate versus the comparator linezolid (Zyvox(R)) in patients with acute bacterial skin and skin structure infections (ABSSSI).

TSRX is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, tedizolid phosphate, is a once-daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the company's tedizolid phosphate clinical program, Trius has initiated IND-enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of three preclinical programs fully supported by federal contracts.

For more information about TSRX please visit http://www.triusrx.com

To read the full article visit URL http://crweselect.com/28287/stock-alerts/apa-ctic-tsrx-crweselectcom-stock-news-apache-corporation-cell-therapeutics-trius-therapeutics-video-included-inside/

****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

APAcrweselect0123
CTICcrweselect0123
TSRXcrweselect0123

APA     apache corporation     Cell Therapeutics     Cordillera Energy Partners     CTIC     Pixuvri     Trius Therapeutics     TSRX